Indian Journal of Medical Biochemistry

Register      Login

VOLUME 24 , ISSUE 1 ( January-April, 2020 ) > List of Articles

Original Article

Evaluation of High-sensitivity C-reactive Protein and Lipid Profile in Nondiabetic Siblings and Offspring of Type 2 Diabetes Mellitus Patients

Kamalakar B Mane, Shilpa Asegaonkar

Citation Information : Mane KB, Asegaonkar S. Evaluation of High-sensitivity C-reactive Protein and Lipid Profile in Nondiabetic Siblings and Offspring of Type 2 Diabetes Mellitus Patients. Indian J Med Biochem 2020; 24 (1):32-36.

DOI: 10.5005/jp-journals-10054-0135

License: CC BY-NC 4.0

Published Online: 03-11-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Introduction: Onset of type 2 diabetes mellitus (T2DM) at early age heralds many years of disease and an increased risk that the full range of both microvascular and macrovascular complications will occur when affected individuals are still relatively young. Thus, further generations may be burdened with morbidity and mortality at the height of their productivity, potentially affecting workface, and healthcare systems of countries across the world. Materials and methods: The present study carried out at Department of Biochemistry at tertiary care hospital; total 100 nondiabetic siblings and offspring of T2DM patients between the age group 20 and 50 years selected on outpatient department (OPD) basis and compared with 100 age- and sex-matched healthy controls. Serum tested for plasma glucose level, serum high-sensitivity C-reactive protein (hs-CRP), serum cholesterol, serum triglycerides (TGs), and high-density lipoprotein (HDL) levels. Results: The mean value of blood sugar level did not show significant difference between the cases and controls (92.02 ± 9.23 vs 91.77 ± 7.99, p ≥ 0.05). The mean values of hs-CRP (2.4 ± 1.98 vs 1.0 ± 0.38), TG (167.35 ± 17.35 vs 124.63 ± 13.55), total cholesterol (TC) (176.99 ± 12.45 vs 147.59 ± 9.72), low-density lipoprotein (LDL) (106.41 ± 12.99 vs 71.65 ± 11.24), and very high-density lipoprotein (VHDL) (33.47 ± 3.47 vs 24.93 ± 2.71) (all p < 0.001) were increased, however mean value of HDL (37.11 ± 3.99 vs 51.01 ± 3.93) was decreased in the cases as compared to controls. High-sensitivity C-reactive protein shows positive correlation with TG, TC, LDL, and very low-density lipoprotein and has negative correlation with HDL. Conclusion: Timely screening and early detection of the increased hs-CRP in the first-degree relatives of T2DM subjects may help clinicians enable to intervene early in the course of disease and to prevent further complications and outcomes. Therefore, primary prevention by target screening among high-risk individuals to prevent transition to overt T2DM by therapeutic lifestyle changes is a feasible and attractive alternative to reduce diabetes-related morbidity and mortality.

PDF Share
  1. Ramachandran A, Snehalatha C. Current scenario of diabetes in India. J Diabetes 2009;1(1):18–28. DOI: 10.1111/j.1753-0407.2008.00004.x.
  2. Mohan V, Sandeep S, Deepa R, et al. Epidemiology of type II diabetes: Indian scenario. Indian J Med Res 2007;125(3):217–230.
  3. Alberti G, Zimmet P, Shaw P, et al. Type II diabetes in the young: the evolving epidemic. Diabetes Care 2004;27(7):1798–1811. DOI: 10.2337/diacare.27.7.1798.
  4. World Health Organization. Report of a WHO consultation, definition, diagnosis and classification of diabetes mellitus and its complication: WHO, department of non-communicable disease surveillance. Geneva 1999. 1–59.
  5. Ridderstrale M, Groop L. Genetic dissection of type II diabetes. Mol Cell Endocrinol 2009;297(1–2):10–17. DOI: 10.1016/j.mce.2008.10.002.
  6. Ramachandran A, Snehalatha C. Type II diabetes mellitus—the epidemic of the 21st century: the Indian scenario. Int J Diab Dev Countries 1999;19:158–164.
  7. Carmena R. High risk of lipoprotein dysfunction in type II diabetes mellitus. Rev Esp Cardiol 2008;8(Supl C):18–24.
  8. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001;86(3):965–971. DOI: 10.1210/jcem.86.3.7304.
  9. Shishehmbor MH, Bhatt DL, Topol EJ, et al. Using C-reactive protein to asses cardiovascular disease risk. ClevClin J Med 2003;70(7):634–640.
  10. Chandalia M, Cabo-Chan AV, Devaraj S, et al. Elevated plasma high-sensitivity C-reactive protein concentrations in asian indians living in the United States. J Clin Endocrinol Metab 2003;88(8):3773–3776. DOI: 10.1210/jc.2003-030301.
  11. Papazafiropoulou A, Sotiropoulos A, Skliros E, et al. Familial history of diabetes and clinical characteristics in greek subjects with type II diabetes. BMC Endocr Disord 2009;9:12. DOI: 10.1186/1472-6823- 9-12.
  12. Gelaye B, Revilla L, Lopez T, et al. Association between insulin resistance and C-reactive protein among peruvian adults. Diabetol Metab Syndr 2010;2(1):30. DOI: 10.1186/1758-5996-2-30.
  13. Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47(8):1403–1410. DOI: 10.1007/s00125-004-1472-x.
  14. Hojbjerre L, Sonne MP, Alibegovic AC, et al. Impact of physical inactivity on adipose tissue low-grade inflammation in first-degree relatives of type II diabetics. Diabetes Care 2011;34(10):2265–2272. DOI: 10.2337/dc11-0631.
  15. Zehua Z, Wang ZH, Zhang SU, et al. High sensitive C-reactive protein level and its clinical significance in normoglycemic first-degree relatives of type II diabetic family. J Pract Med 2009.
  16. Kriketos AD, Greenfield JR, Peake PW, et al. Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type II diabetic subjects. Diabetes Care 2004;27(8):2033–2040. DOI: 10.2337/diacare.27.8.2033.
  17. Gulcelik NE, Serter R, Ozkaya M, et al. Association of C-reactive protein with insulin resistance in first degree relatives of diabetic patients. Endocrine 2006;11:329.
  18. Eriksson JW, Buren J, Svensson M, et al. Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type II diabetes patients and healthy control subjects. Atherosclerosis 2003;166(2):359–367. DOI: 10.1016/S0021-9150(02)00366-0.
  19. Sandeep S, Gokulakrishnan K, Velmurugan K, et al. Visceral and subcutaneous abdominal fat in relation to insulin resistance and metabolic syndrome in non-diabetic south Indians. Indian J Med Res 2010;131:629–635.
  20. Taskinen MR. Diabeticdyslipidemia: from basic research to clinical practice. Diabetologia 2003;46(6):733–749. DOI: 10.1007/s00125-003-1111-y.
  21. Axelsen M, Eriksson JW, Taskinen MR, et al. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type II diabetes. Ann Intern Med 1999;131(1):27–31. DOI: 10.7326/0003-4819-131-1-199907060- 00006.
  22. Tian H, Han L, Ren Y, et al. Lipoprotein (a) level and lipids in type II diabetic patients and their normoglycemic first-degree relatives in type II diabetic pedigrees. Diabetes Res Clin Pract 2003;59(1):63–69. DOI: 10.1016/S0168-8227(02)00158-4.
  23. Perseghin G, Ghosh S, Gerow K, et al. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997;46(6):1001–1009. DOI: 10.2337/diab.46.6.1001.
  24. Edavan P, Kulshreshtha B, Khurana ML, et al. Low HDL-cholesterol among normal weight, normoglycemic offspring of individuals with type II diabetes mellitus. Hormones 2011;10(1):57–66. DOI: 10.14310/horm.2002.1293.
  25. Deng CX, Ling G, Rong ZH. Relation of high-sensitivity C-reactive protein with insulin resistance in the first-degree relatives of type II diabetics. Chin J Diabetes 2008.
  26. Vikram NK, Misra A, Pandey RM, et al. Association between subclinical inflammation and fasting insulin in urban young adult north Indian males. IJMR 2006;124(6):677–682.
  27. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type II diabetes mellitus. JAMA 2001;286(3):327–334. DOI: 10.1001/jama.286. 3.327.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.